nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—PDE5A—Pentoxifylline—systemic scleroderma	0.366	0.547	CbGbCtD
Dipyridamole—PDE4A—Pentoxifylline—systemic scleroderma	0.21	0.314	CbGbCtD
Dipyridamole—ABCC4—Methotrexate—systemic scleroderma	0.0265	0.0397	CbGbCtD
Dipyridamole—ABCB1—Lisinopril—systemic scleroderma	0.0218	0.0326	CbGbCtD
Dipyridamole—ABCB1—Captopril—systemic scleroderma	0.0163	0.0244	CbGbCtD
Dipyridamole—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0128	0.0192	CbGbCtD
Dipyridamole—ABCB1—Prednisone—systemic scleroderma	0.0103	0.0153	CbGbCtD
Dipyridamole—PDE5A—pulmonary artery—systemic scleroderma	0.00865	0.107	CbGeAlD
Dipyridamole—ABCB1—Methotrexate—systemic scleroderma	0.00515	0.0077	CbGbCtD
Dipyridamole—PDE6B—connective tissue—systemic scleroderma	0.00362	0.0448	CbGeAlD
Dipyridamole—PDE5A—artery—systemic scleroderma	0.00321	0.0397	CbGeAlD
Dipyridamole—PDE5A—endothelium—systemic scleroderma	0.00271	0.0335	CbGeAlD
Dipyridamole—PRUNE—tendon—systemic scleroderma	0.00262	0.0324	CbGeAlD
Dipyridamole—PDE1C—lung—systemic scleroderma	0.00255	0.0316	CbGeAlD
Dipyridamole—PDE5A—blood vessel—systemic scleroderma	0.0025	0.0309	CbGeAlD
Dipyridamole—PDE11A—tendon—systemic scleroderma	0.00232	0.0286	CbGeAlD
Dipyridamole—PRUNE—lung—systemic scleroderma	0.0023	0.0285	CbGeAlD
Dipyridamole—PDE6D—lung—systemic scleroderma	0.00222	0.0275	CbGeAlD
Dipyridamole—PDE6B—lung—systemic scleroderma	0.00219	0.027	CbGeAlD
Dipyridamole—PDE3B—connective tissue—systemic scleroderma	0.00204	0.0253	CbGeAlD
Dipyridamole—PDE6G—lung—systemic scleroderma	0.00196	0.0242	CbGeAlD
Dipyridamole—PDE7B—tendon—systemic scleroderma	0.0018	0.0223	CbGeAlD
Dipyridamole—PDE8A—smooth muscle tissue—systemic scleroderma	0.00172	0.0213	CbGeAlD
Dipyridamole—PDE1A—smooth muscle tissue—systemic scleroderma	0.00166	0.0206	CbGeAlD
Dipyridamole—PDE7B—lung—systemic scleroderma	0.00158	0.0196	CbGeAlD
Dipyridamole—PDE10A—digestive system—systemic scleroderma	0.00158	0.0196	CbGeAlD
Dipyridamole—ADA—connective tissue—systemic scleroderma	0.00155	0.0191	CbGeAlD
Dipyridamole—PDE2A—tendon—systemic scleroderma	0.00151	0.0186	CbGeAlD
Dipyridamole—PDE10A—tendon—systemic scleroderma	0.00151	0.0186	CbGeAlD
Dipyridamole—PDE10A—lung—systemic scleroderma	0.00132	0.0163	CbGeAlD
Dipyridamole—PDE2A—lung—systemic scleroderma	0.00132	0.0163	CbGeAlD
Dipyridamole—PDE8A—tendon—systemic scleroderma	0.00129	0.016	CbGeAlD
Dipyridamole—PDE5A—connective tissue—systemic scleroderma	0.00128	0.0159	CbGeAlD
Dipyridamole—PDE8B—lung—systemic scleroderma	0.00126	0.0156	CbGeAlD
Dipyridamole—PDE1A—tendon—systemic scleroderma	0.00125	0.0155	CbGeAlD
Dipyridamole—PDE3B—lung—systemic scleroderma	0.00123	0.0152	CbGeAlD
Dipyridamole—PDE5A—smooth muscle tissue—systemic scleroderma	0.00117	0.0145	CbGeAlD
Dipyridamole—PDE3A—smooth muscle tissue—systemic scleroderma	0.00114	0.0141	CbGeAlD
Dipyridamole—PDE8A—lung—systemic scleroderma	0.00113	0.014	CbGeAlD
Dipyridamole—ADA—digestive system—systemic scleroderma	0.00112	0.0138	CbGeAlD
Dipyridamole—PDE1A—lung—systemic scleroderma	0.0011	0.0136	CbGeAlD
Dipyridamole—SLC29A1—connective tissue—systemic scleroderma	0.00108	0.0133	CbGeAlD
Dipyridamole—ADA—tendon—systemic scleroderma	0.00106	0.0132	CbGeAlD
Dipyridamole—ADA—lung—systemic scleroderma	0.000933	0.0115	CbGeAlD
Dipyridamole—PDE5A—digestive system—systemic scleroderma	0.000926	0.0115	CbGeAlD
Dipyridamole—PDE4A—lung—systemic scleroderma	0.000909	0.0112	CbGeAlD
Dipyridamole—PDE5A—tendon—systemic scleroderma	0.000881	0.0109	CbGeAlD
Dipyridamole—PDE3A—tendon—systemic scleroderma	0.000857	0.0106	CbGeAlD
Dipyridamole—ABCC5—tendon—systemic scleroderma	0.000806	0.00997	CbGeAlD
Dipyridamole—SLC29A1—digestive system—systemic scleroderma	0.000777	0.00962	CbGeAlD
Dipyridamole—PDE5A—lung—systemic scleroderma	0.000773	0.00957	CbGeAlD
Dipyridamole—PDE3A—lung—systemic scleroderma	0.000752	0.0093	CbGeAlD
Dipyridamole—SLC29A1—tendon—systemic scleroderma	0.00074	0.00915	CbGeAlD
Dipyridamole—ABCC5—lung—systemic scleroderma	0.000707	0.00875	CbGeAlD
Dipyridamole—SLC29A1—lung—systemic scleroderma	0.000649	0.00803	CbGeAlD
Dipyridamole—ABCC4—digestive system—systemic scleroderma	0.000587	0.00726	CbGeAlD
Dipyridamole—ABCC4—tendon—systemic scleroderma	0.000558	0.00691	CbGeAlD
Dipyridamole—ABCB1—blood vessel—systemic scleroderma	0.000552	0.00682	CbGeAlD
Dipyridamole—ABCC4—lung—systemic scleroderma	0.00049	0.00606	CbGeAlD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000208	0.00106	CcSEcCtD
Dipyridamole—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00105	CcSEcCtD
Dipyridamole—Discomfort—Lisinopril—systemic scleroderma	0.000207	0.00105	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000207	0.00105	CcSEcCtD
Dipyridamole—Dyspepsia—Leflunomide—systemic scleroderma	0.000206	0.00104	CcSEcCtD
Dipyridamole—Vomiting—Mometasone—systemic scleroderma	0.000206	0.00104	CcSEcCtD
Dipyridamole—Dry mouth—Lisinopril—systemic scleroderma	0.000205	0.00104	CcSEcCtD
Dipyridamole—Sweating increased—Prednisone—systemic scleroderma	0.000205	0.00104	CcSEcCtD
Dipyridamole—Feeling abnormal—Azathioprine—systemic scleroderma	0.000204	0.00104	CcSEcCtD
Dipyridamole—ABCB1—digestive system—systemic scleroderma	0.000204	0.00253	CbGeAlD
Dipyridamole—Rash—Mometasone—systemic scleroderma	0.000204	0.00103	CcSEcCtD
Dipyridamole—Asthenia—Captopril—systemic scleroderma	0.000204	0.00103	CcSEcCtD
Dipyridamole—Dermatitis—Mometasone—systemic scleroderma	0.000204	0.00103	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000203	0.00103	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000203	0.00103	CcSEcCtD
Dipyridamole—Headache—Mometasone—systemic scleroderma	0.000203	0.00103	CcSEcCtD
Dipyridamole—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000202	0.00103	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000202	0.00102	CcSEcCtD
Dipyridamole—Fatigue—Leflunomide—systemic scleroderma	0.000202	0.00102	CcSEcCtD
Dipyridamole—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000201	0.00102	CcSEcCtD
Dipyridamole—Oedema—Lisinopril—systemic scleroderma	0.000201	0.00102	CcSEcCtD
Dipyridamole—Pruritus—Captopril—systemic scleroderma	0.000201	0.00102	CcSEcCtD
Dipyridamole—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000201	0.00102	CcSEcCtD
Dipyridamole—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00102	CcSEcCtD
Dipyridamole—Pain—Leflunomide—systemic scleroderma	0.0002	0.00102	CcSEcCtD
Dipyridamole—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00101	CcSEcCtD
Dipyridamole—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000199	0.00101	CcSEcCtD
Dipyridamole—Somnolence—Mycophenolic acid—systemic scleroderma	0.000199	0.00101	CcSEcCtD
Dipyridamole—Shock—Lisinopril—systemic scleroderma	0.000198	0.001	CcSEcCtD
Dipyridamole—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000197	0.001	CcSEcCtD
Dipyridamole—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000197	0.000999	CcSEcCtD
Dipyridamole—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000197	0.000997	CcSEcCtD
Dipyridamole—Tachycardia—Lisinopril—systemic scleroderma	0.000196	0.000996	CcSEcCtD
Dipyridamole—Abdominal pain—Azathioprine—systemic scleroderma	0.000196	0.000994	CcSEcCtD
Dipyridamole—Skin disorder—Lisinopril—systemic scleroderma	0.000195	0.000991	CcSEcCtD
Dipyridamole—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000988	CcSEcCtD
Dipyridamole—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000194	0.000986	CcSEcCtD
Dipyridamole—Diarrhoea—Captopril—systemic scleroderma	0.000194	0.000985	CcSEcCtD
Dipyridamole—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000984	CcSEcCtD
Dipyridamole—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000982	CcSEcCtD
Dipyridamole—Feeling abnormal—Leflunomide—systemic scleroderma	0.000193	0.000978	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000193	0.000978	CcSEcCtD
Dipyridamole—Fatigue—Mycophenolic acid—systemic scleroderma	0.000193	0.000976	CcSEcCtD
Dipyridamole—Nausea—Mometasone—systemic scleroderma	0.000192	0.000974	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000191	0.000971	CcSEcCtD
Dipyridamole—Pain—Mycophenolic acid—systemic scleroderma	0.000191	0.000968	CcSEcCtD
Dipyridamole—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000968	CcSEcCtD
Dipyridamole—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000962	CcSEcCtD
Dipyridamole—Cough—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000956	CcSEcCtD
Dipyridamole—Hypotension—Lisinopril—systemic scleroderma	0.000188	0.000953	CcSEcCtD
Dipyridamole—Dizziness—Captopril—systemic scleroderma	0.000188	0.000952	CcSEcCtD
Dipyridamole—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000949	CcSEcCtD
Dipyridamole—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000945	CcSEcCtD
Dipyridamole—Urticaria—Leflunomide—systemic scleroderma	0.000186	0.000943	CcSEcCtD
Dipyridamole—Abdominal pain—Leflunomide—systemic scleroderma	0.000185	0.000938	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000185	0.000936	CcSEcCtD
Dipyridamole—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000184	0.000933	CcSEcCtD
Dipyridamole—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000932	CcSEcCtD
Dipyridamole—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000932	CcSEcCtD
Dipyridamole—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000932	CcSEcCtD
Dipyridamole—Myocardial infarction—Prednisone—systemic scleroderma	0.000184	0.000931	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000183	0.000929	CcSEcCtD
Dipyridamole—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000929	CcSEcCtD
Dipyridamole—Hypersensitivity—Azathioprine—systemic scleroderma	0.000183	0.000926	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000183	0.000926	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000926	CcSEcCtD
Dipyridamole—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000921	CcSEcCtD
Dipyridamole—Paraesthesia—Lisinopril—systemic scleroderma	0.000181	0.000916	CcSEcCtD
Dipyridamole—Vomiting—Captopril—systemic scleroderma	0.000181	0.000916	CcSEcCtD
Dipyridamole—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000912	CcSEcCtD
Dipyridamole—Dyspnoea—Lisinopril—systemic scleroderma	0.000179	0.000909	CcSEcCtD
Dipyridamole—Rash—Captopril—systemic scleroderma	0.000179	0.000908	CcSEcCtD
Dipyridamole—Dermatitis—Captopril—systemic scleroderma	0.000179	0.000907	CcSEcCtD
Dipyridamole—Somnolence—Lisinopril—systemic scleroderma	0.000179	0.000907	CcSEcCtD
Dipyridamole—Headache—Captopril—systemic scleroderma	0.000178	0.000902	CcSEcCtD
Dipyridamole—Dyspepsia—Lisinopril—systemic scleroderma	0.000177	0.000898	CcSEcCtD
Dipyridamole—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000177	0.000895	CcSEcCtD
Dipyridamole—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000894	CcSEcCtD
Dipyridamole—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000894	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000174	0.000881	CcSEcCtD
Dipyridamole—Fatigue—Lisinopril—systemic scleroderma	0.000173	0.000879	CcSEcCtD
Dipyridamole—Shock—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000879	CcSEcCtD
Dipyridamole—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000876	CcSEcCtD
Dipyridamole—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000875	CcSEcCtD
Dipyridamole—Hypersensitivity—Leflunomide—systemic scleroderma	0.000172	0.000875	CcSEcCtD
Dipyridamole—Pain—Lisinopril—systemic scleroderma	0.000172	0.000872	CcSEcCtD
Dipyridamole—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000172	0.000872	CcSEcCtD
Dipyridamole—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000868	CcSEcCtD
Dipyridamole—Bradycardia—Prednisone—systemic scleroderma	0.000171	0.000868	CcSEcCtD
Dipyridamole—ABCB1—lung—systemic scleroderma	0.000171	0.00211	CbGeAlD
Dipyridamole—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00017	0.000864	CcSEcCtD
Dipyridamole—Diarrhoea—Azathioprine—systemic scleroderma	0.00017	0.00086	CcSEcCtD
Dipyridamole—Haemoglobin—Prednisone—systemic scleroderma	0.000169	0.000857	CcSEcCtD
Dipyridamole—Nausea—Captopril—systemic scleroderma	0.000169	0.000856	CcSEcCtD
Dipyridamole—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000168	0.000854	CcSEcCtD
Dipyridamole—Haemorrhage—Prednisone—systemic scleroderma	0.000168	0.000853	CcSEcCtD
Dipyridamole—Asthenia—Leflunomide—systemic scleroderma	0.000168	0.000852	CcSEcCtD
Dipyridamole—Feeling abnormal—Lisinopril—systemic scleroderma	0.000166	0.000841	CcSEcCtD
Dipyridamole—Pruritus—Leflunomide—systemic scleroderma	0.000166	0.00084	CcSEcCtD
Dipyridamole—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000835	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000164	0.000834	CcSEcCtD
Dipyridamole—Dizziness—Azathioprine—systemic scleroderma	0.000164	0.000831	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000161	0.000814	CcSEcCtD
Dipyridamole—Asthenia—Mycophenolic acid—systemic scleroderma	0.00016	0.000813	CcSEcCtD
Dipyridamole—Diarrhoea—Leflunomide—systemic scleroderma	0.00016	0.000812	CcSEcCtD
Dipyridamole—Urticaria—Lisinopril—systemic scleroderma	0.00016	0.00081	CcSEcCtD
Dipyridamole—Abdominal pain—Lisinopril—systemic scleroderma	0.000159	0.000806	CcSEcCtD
Dipyridamole—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000803	CcSEcCtD
Dipyridamole—Pruritus—Mycophenolic acid—systemic scleroderma	0.000158	0.000801	CcSEcCtD
Dipyridamole—Vomiting—Azathioprine—systemic scleroderma	0.000158	0.000799	CcSEcCtD
Dipyridamole—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000797	CcSEcCtD
Dipyridamole—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000795	CcSEcCtD
Dipyridamole—Rash—Azathioprine—systemic scleroderma	0.000156	0.000793	CcSEcCtD
Dipyridamole—Dermatitis—Azathioprine—systemic scleroderma	0.000156	0.000792	CcSEcCtD
Dipyridamole—Flushing—Prednisone—systemic scleroderma	0.000156	0.000791	CcSEcCtD
Dipyridamole—Headache—Azathioprine—systemic scleroderma	0.000155	0.000787	CcSEcCtD
Dipyridamole—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000787	CcSEcCtD
Dipyridamole—Dizziness—Leflunomide—systemic scleroderma	0.000155	0.000785	CcSEcCtD
Dipyridamole—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000153	0.000775	CcSEcCtD
Dipyridamole—Angiopathy—Prednisone—systemic scleroderma	0.000153	0.000774	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000772	CcSEcCtD
Dipyridamole—Immune system disorder—Prednisone—systemic scleroderma	0.000152	0.00077	CcSEcCtD
Dipyridamole—Pain—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000764	CcSEcCtD
Dipyridamole—Arrhythmia—Prednisone—systemic scleroderma	0.00015	0.000762	CcSEcCtD
Dipyridamole—Vomiting—Leflunomide—systemic scleroderma	0.000149	0.000755	CcSEcCtD
Dipyridamole—Alopecia—Prednisone—systemic scleroderma	0.000149	0.000753	CcSEcCtD
Dipyridamole—Hypersensitivity—Lisinopril—systemic scleroderma	0.000148	0.000752	CcSEcCtD
Dipyridamole—Dizziness—Mycophenolic acid—systemic scleroderma	0.000148	0.000749	CcSEcCtD
Dipyridamole—Rash—Leflunomide—systemic scleroderma	0.000148	0.000748	CcSEcCtD
Dipyridamole—Dermatitis—Leflunomide—systemic scleroderma	0.000147	0.000748	CcSEcCtD
Dipyridamole—Nausea—Azathioprine—systemic scleroderma	0.000147	0.000747	CcSEcCtD
Dipyridamole—Headache—Leflunomide—systemic scleroderma	0.000147	0.000744	CcSEcCtD
Dipyridamole—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000736	CcSEcCtD
Dipyridamole—Asthenia—Lisinopril—systemic scleroderma	0.000144	0.000732	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000731	CcSEcCtD
Dipyridamole—Pruritus—Lisinopril—systemic scleroderma	0.000142	0.000722	CcSEcCtD
Dipyridamole—Vomiting—Mycophenolic acid—systemic scleroderma	0.000142	0.00072	CcSEcCtD
Dipyridamole—Haemoglobin—Methotrexate—systemic scleroderma	0.000141	0.000716	CcSEcCtD
Dipyridamole—Rash—Mycophenolic acid—systemic scleroderma	0.000141	0.000714	CcSEcCtD
Dipyridamole—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000141	0.000713	CcSEcCtD
Dipyridamole—Haemorrhage—Methotrexate—systemic scleroderma	0.000141	0.000713	CcSEcCtD
Dipyridamole—Hepatitis—Methotrexate—systemic scleroderma	0.000141	0.000713	CcSEcCtD
Dipyridamole—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00014	0.00071	CcSEcCtD
Dipyridamole—Headache—Mycophenolic acid—systemic scleroderma	0.00014	0.000709	CcSEcCtD
Dipyridamole—Pharyngitis—Methotrexate—systemic scleroderma	0.000139	0.000707	CcSEcCtD
Dipyridamole—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000706	CcSEcCtD
Dipyridamole—Nausea—Leflunomide—systemic scleroderma	0.000139	0.000705	CcSEcCtD
Dipyridamole—Diarrhoea—Lisinopril—systemic scleroderma	0.000138	0.000698	CcSEcCtD
Dipyridamole—Ill-defined disorder—Prednisone—systemic scleroderma	0.000136	0.000689	CcSEcCtD
Dipyridamole—Anaemia—Prednisone—systemic scleroderma	0.000135	0.000686	CcSEcCtD
Dipyridamole—Angioedema—Prednisone—systemic scleroderma	0.000134	0.000678	CcSEcCtD
Dipyridamole—Dizziness—Lisinopril—systemic scleroderma	0.000133	0.000675	CcSEcCtD
Dipyridamole—Nausea—Mycophenolic acid—systemic scleroderma	0.000133	0.000673	CcSEcCtD
Dipyridamole—Malaise—Prednisone—systemic scleroderma	0.000132	0.000669	CcSEcCtD
Dipyridamole—Vertigo—Prednisone—systemic scleroderma	0.000132	0.000667	CcSEcCtD
Dipyridamole—Syncope—Prednisone—systemic scleroderma	0.000131	0.000666	CcSEcCtD
Dipyridamole—Tinnitus—Methotrexate—systemic scleroderma	0.000131	0.000664	CcSEcCtD
Dipyridamole—Cardiac disorder—Methotrexate—systemic scleroderma	0.00013	0.000661	CcSEcCtD
Dipyridamole—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000658	CcSEcCtD
Dipyridamole—Loss of consciousness—Prednisone—systemic scleroderma	0.000129	0.000652	CcSEcCtD
Dipyridamole—Vomiting—Lisinopril—systemic scleroderma	0.000128	0.000649	CcSEcCtD
Dipyridamole—Angiopathy—Methotrexate—systemic scleroderma	0.000127	0.000647	CcSEcCtD
Dipyridamole—Immune system disorder—Methotrexate—systemic scleroderma	0.000127	0.000644	CcSEcCtD
Dipyridamole—Rash—Lisinopril—systemic scleroderma	0.000127	0.000643	CcSEcCtD
Dipyridamole—Convulsion—Prednisone—systemic scleroderma	0.000127	0.000643	CcSEcCtD
Dipyridamole—Dermatitis—Lisinopril—systemic scleroderma	0.000127	0.000643	CcSEcCtD
Dipyridamole—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000127	0.000642	CcSEcCtD
Dipyridamole—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000641	CcSEcCtD
Dipyridamole—Hypertension—Prednisone—systemic scleroderma	0.000126	0.000641	CcSEcCtD
Dipyridamole—Chills—Methotrexate—systemic scleroderma	0.000126	0.000639	CcSEcCtD
Dipyridamole—Headache—Lisinopril—systemic scleroderma	0.000126	0.000639	CcSEcCtD
Dipyridamole—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000632	CcSEcCtD
Dipyridamole—Arthralgia—Prednisone—systemic scleroderma	0.000125	0.000632	CcSEcCtD
Dipyridamole—Myalgia—Prednisone—systemic scleroderma	0.000125	0.000632	CcSEcCtD
Dipyridamole—Anxiety—Prednisone—systemic scleroderma	0.000124	0.00063	CcSEcCtD
Dipyridamole—Alopecia—Methotrexate—systemic scleroderma	0.000124	0.00063	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000124	0.000628	CcSEcCtD
Dipyridamole—Discomfort—Prednisone—systemic scleroderma	0.000123	0.000624	CcSEcCtD
Dipyridamole—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000611	CcSEcCtD
Dipyridamole—Dysgeusia—Methotrexate—systemic scleroderma	0.00012	0.000607	CcSEcCtD
Dipyridamole—Nausea—Lisinopril—systemic scleroderma	0.000119	0.000606	CcSEcCtD
Dipyridamole—Oedema—Prednisone—systemic scleroderma	0.000119	0.000606	CcSEcCtD
Dipyridamole—Anaphylactic shock—Prednisone—systemic scleroderma	0.000119	0.000606	CcSEcCtD
Dipyridamole—Back pain—Methotrexate—systemic scleroderma	0.000118	0.0006	CcSEcCtD
Dipyridamole—Shock—Prednisone—systemic scleroderma	0.000118	0.000596	CcSEcCtD
Dipyridamole—Nervous system disorder—Prednisone—systemic scleroderma	0.000117	0.000594	CcSEcCtD
Dipyridamole—Tachycardia—Prednisone—systemic scleroderma	0.000117	0.000591	CcSEcCtD
Dipyridamole—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000591	CcSEcCtD
Dipyridamole—Skin disorder—Prednisone—systemic scleroderma	0.000116	0.000588	CcSEcCtD
Dipyridamole—Hyperhidrosis—Prednisone—systemic scleroderma	0.000115	0.000586	CcSEcCtD
Dipyridamole—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000114	0.000576	CcSEcCtD
Dipyridamole—Anaemia—Methotrexate—systemic scleroderma	0.000113	0.000573	CcSEcCtD
Dipyridamole—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000568	CcSEcCtD
Dipyridamole—Rash—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000564	CcSEcCtD
Dipyridamole—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000563	CcSEcCtD
Dipyridamole—Headache—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00056	CcSEcCtD
Dipyridamole—Malaise—Methotrexate—systemic scleroderma	0.00011	0.000559	CcSEcCtD
Dipyridamole—Vertigo—Methotrexate—systemic scleroderma	0.00011	0.000557	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000109	0.000552	CcSEcCtD
Dipyridamole—Paraesthesia—Prednisone—systemic scleroderma	0.000107	0.000544	CcSEcCtD
Dipyridamole—Cough—Methotrexate—systemic scleroderma	0.000107	0.000541	CcSEcCtD
Dipyridamole—Convulsion—Methotrexate—systemic scleroderma	0.000106	0.000537	CcSEcCtD
Dipyridamole—Dyspepsia—Prednisone—systemic scleroderma	0.000105	0.000533	CcSEcCtD
Dipyridamole—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000531	CcSEcCtD
Dipyridamole—Chest pain—Methotrexate—systemic scleroderma	0.000104	0.000528	CcSEcCtD
Dipyridamole—Arthralgia—Methotrexate—systemic scleroderma	0.000104	0.000528	CcSEcCtD
Dipyridamole—Myalgia—Methotrexate—systemic scleroderma	0.000104	0.000528	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000103	0.000524	CcSEcCtD
Dipyridamole—Fatigue—Prednisone—systemic scleroderma	0.000103	0.000522	CcSEcCtD
Dipyridamole—Discomfort—Methotrexate—systemic scleroderma	0.000103	0.000522	CcSEcCtD
Dipyridamole—Anaphylactic shock—Methotrexate—systemic scleroderma	9.98e-05	0.000506	CcSEcCtD
Dipyridamole—Feeling abnormal—Prednisone—systemic scleroderma	9.84e-05	0.000499	CcSEcCtD
Dipyridamole—Nervous system disorder—Methotrexate—systemic scleroderma	9.79e-05	0.000497	CcSEcCtD
Dipyridamole—Thrombocytopenia—Methotrexate—systemic scleroderma	9.78e-05	0.000496	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Prednisone—systemic scleroderma	9.77e-05	0.000495	CcSEcCtD
Dipyridamole—Skin disorder—Methotrexate—systemic scleroderma	9.7e-05	0.000492	CcSEcCtD
Dipyridamole—Hyperhidrosis—Methotrexate—systemic scleroderma	9.65e-05	0.000489	CcSEcCtD
Dipyridamole—Urticaria—Prednisone—systemic scleroderma	9.49e-05	0.000481	CcSEcCtD
Dipyridamole—Abdominal pain—Prednisone—systemic scleroderma	9.44e-05	0.000479	CcSEcCtD
Dipyridamole—Hypotension—Methotrexate—systemic scleroderma	9.33e-05	0.000473	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.1e-05	0.000461	CcSEcCtD
Dipyridamole—Paraesthesia—Methotrexate—systemic scleroderma	8.97e-05	0.000455	CcSEcCtD
Dipyridamole—Dyspnoea—Methotrexate—systemic scleroderma	8.9e-05	0.000451	CcSEcCtD
Dipyridamole—Somnolence—Methotrexate—systemic scleroderma	8.88e-05	0.00045	CcSEcCtD
Dipyridamole—Hypersensitivity—Prednisone—systemic scleroderma	8.8e-05	0.000446	CcSEcCtD
Dipyridamole—Dyspepsia—Methotrexate—systemic scleroderma	8.79e-05	0.000446	CcSEcCtD
Dipyridamole—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	8.79e-05	0.00165	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HSPG2—systemic scleroderma	8.77e-05	0.00165	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HSPG2—systemic scleroderma	8.77e-05	0.00165	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—CTLA4—systemic scleroderma	8.65e-05	0.00163	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—EDN1—systemic scleroderma	8.64e-05	0.00162	CbGpPWpGaD
Dipyridamole—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.62e-05	0.000437	CcSEcCtD
Dipyridamole—PDE1C—Signaling Pathways—RHOB—systemic scleroderma	8.62e-05	0.00162	CbGpPWpGaD
Dipyridamole—Fatigue—Methotrexate—systemic scleroderma	8.61e-05	0.000436	CcSEcCtD
Dipyridamole—Asthenia—Prednisone—systemic scleroderma	8.57e-05	0.000435	CcSEcCtD
Dipyridamole—PDE1A—GPCR downstream signaling—RHOB—systemic scleroderma	8.56e-05	0.00161	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—CSK—systemic scleroderma	8.55e-05	0.00161	CbGpPWpGaD
Dipyridamole—Pain—Methotrexate—systemic scleroderma	8.54e-05	0.000433	CcSEcCtD
Dipyridamole—PDE11A—Hemostasis—NOS3—systemic scleroderma	8.53e-05	0.0016	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—RHOB—systemic scleroderma	8.5e-05	0.0016	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—RHOB—systemic scleroderma	8.5e-05	0.0016	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—SMAD7—systemic scleroderma	8.48e-05	0.00159	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—SMAD7—systemic scleroderma	8.48e-05	0.00159	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—CSK—systemic scleroderma	8.47e-05	0.00159	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—CSK—systemic scleroderma	8.47e-05	0.00159	CbGpPWpGaD
Dipyridamole—Pruritus—Prednisone—systemic scleroderma	8.45e-05	0.000429	CcSEcCtD
Dipyridamole—ABCC4—Platelet degranulation—TGFB1—systemic scleroderma	8.45e-05	0.00159	CbGpPWpGaD
Dipyridamole—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	8.35e-05	0.00157	CbGpPWpGaD
Dipyridamole—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	8.3e-05	0.00156	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—RHOB—systemic scleroderma	8.29e-05	0.00156	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—RHOB—systemic scleroderma	8.27e-05	0.00155	CbGpPWpGaD
Dipyridamole—Feeling abnormal—Methotrexate—systemic scleroderma	8.23e-05	0.000417	CcSEcCtD
Dipyridamole—Diarrhoea—Prednisone—systemic scleroderma	8.17e-05	0.000414	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.16e-05	0.000414	CcSEcCtD
Dipyridamole—PDE1C—Signaling Pathways—HSPG2—systemic scleroderma	8.13e-05	0.00153	CbGpPWpGaD
Dipyridamole—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	8.05e-05	0.00151	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—ITGAM—systemic scleroderma	8.04e-05	0.00151	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—EDN1—systemic scleroderma	8.03e-05	0.00151	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—EDN1—systemic scleroderma	8.03e-05	0.00151	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HSPG2—systemic scleroderma	8.02e-05	0.00151	CbGpPWpGaD
Dipyridamole—Urticaria—Methotrexate—systemic scleroderma	7.93e-05	0.000402	CcSEcCtD
Dipyridamole—Dizziness—Prednisone—systemic scleroderma	7.9e-05	0.000401	CcSEcCtD
Dipyridamole—Abdominal pain—Methotrexate—systemic scleroderma	7.89e-05	0.0004	CcSEcCtD
Dipyridamole—PDE10A—GPCR downstream signaling—EDN1—systemic scleroderma	7.89e-05	0.00148	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—CSK—systemic scleroderma	7.85e-05	0.00147	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—RHOB—systemic scleroderma	7.83e-05	0.00147	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HSPG2—systemic scleroderma	7.81e-05	0.00147	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—RHOB—systemic scleroderma	7.77e-05	0.00146	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—SMAD7—systemic scleroderma	7.75e-05	0.00146	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFBI—systemic scleroderma	7.75e-05	0.00146	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFBI—systemic scleroderma	7.75e-05	0.00146	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—CSK—systemic scleroderma	7.74e-05	0.00145	CbGpPWpGaD
Dipyridamole—PDE5A—Hemostasis—NOS3—systemic scleroderma	7.6e-05	0.00143	CbGpPWpGaD
Dipyridamole—PDE10A—Hemostasis—NOS3—systemic scleroderma	7.6e-05	0.00143	CbGpPWpGaD
Dipyridamole—Vomiting—Prednisone—systemic scleroderma	7.6e-05	0.000385	CcSEcCtD
Dipyridamole—PDE10A—Signaling Pathways—CSK—systemic scleroderma	7.55e-05	0.00142	CbGpPWpGaD
Dipyridamole—Rash—Prednisone—systemic scleroderma	7.53e-05	0.000382	CcSEcCtD
Dipyridamole—ABCC5—NRF2 pathway—TGFB1—systemic scleroderma	7.53e-05	0.00141	CbGpPWpGaD
Dipyridamole—Dermatitis—Prednisone—systemic scleroderma	7.53e-05	0.000382	CcSEcCtD
Dipyridamole—Headache—Prednisone—systemic scleroderma	7.48e-05	0.00038	CcSEcCtD
Dipyridamole—PDE1C—Signaling by GPCR—EDN1—systemic scleroderma	7.45e-05	0.0014	CbGpPWpGaD
Dipyridamole—Hypersensitivity—Methotrexate—systemic scleroderma	7.36e-05	0.000373	CcSEcCtD
Dipyridamole—Asthenia—Methotrexate—systemic scleroderma	7.16e-05	0.000363	CcSEcCtD
Dipyridamole—PDE10A—Signaling by GPCR—EDN1—systemic scleroderma	7.16e-05	0.00135	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—HSPG2—systemic scleroderma	7.13e-05	0.00134	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—HLA-DQB1—systemic scleroderma	7.12e-05	0.00134	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—RHOB—systemic scleroderma	7.11e-05	0.00134	CbGpPWpGaD
Dipyridamole—Nausea—Prednisone—systemic scleroderma	7.1e-05	0.00036	CcSEcCtD
Dipyridamole—PDE1B—Disease—TGFBI—systemic scleroderma	7.09e-05	0.00133	CbGpPWpGaD
Dipyridamole—Pruritus—Methotrexate—systemic scleroderma	7.06e-05	0.000358	CcSEcCtD
Dipyridamole—PDE3B—Signaling Pathways—SMAD7—systemic scleroderma	6.93e-05	0.0013	CbGpPWpGaD
Dipyridamole—Diarrhoea—Methotrexate—systemic scleroderma	6.83e-05	0.000346	CcSEcCtD
Dipyridamole—PDE3B—Hemostasis—MMP1—systemic scleroderma	6.79e-05	0.00128	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—IL1A—systemic scleroderma	6.77e-05	0.00127	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—EDN1—systemic scleroderma	6.74e-05	0.00127	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—EDN1—systemic scleroderma	6.74e-05	0.00127	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—CD40LG—systemic scleroderma	6.73e-05	0.00126	CbGpPWpGaD
Dipyridamole—PDE2A—Hemostasis—TGFB1—systemic scleroderma	6.63e-05	0.00125	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling by GPCR—CCL2—systemic scleroderma	6.63e-05	0.00125	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling by GPCR—CCL2—systemic scleroderma	6.63e-05	0.00125	CbGpPWpGaD
Dipyridamole—Dizziness—Methotrexate—systemic scleroderma	6.6e-05	0.000335	CcSEcCtD
Dipyridamole—PDE4A—Signaling Pathways—SMAD7—systemic scleroderma	6.49e-05	0.00122	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CSK—systemic scleroderma	6.47e-05	0.00122	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—CCL2—systemic scleroderma	6.46e-05	0.00121	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IRF5—systemic scleroderma	6.36e-05	0.0012	CbGpPWpGaD
Dipyridamole—Vomiting—Methotrexate—systemic scleroderma	6.35e-05	0.000322	CcSEcCtD
Dipyridamole—PDE3A—Signaling Pathways—SMAD7—systemic scleroderma	6.31e-05	0.00119	CbGpPWpGaD
Dipyridamole—Rash—Methotrexate—systemic scleroderma	6.3e-05	0.000319	CcSEcCtD
Dipyridamole—Dermatitis—Methotrexate—systemic scleroderma	6.29e-05	0.000319	CcSEcCtD
Dipyridamole—Headache—Methotrexate—systemic scleroderma	6.25e-05	0.000317	CcSEcCtD
Dipyridamole—PDE1A—Disease—HSPG2—systemic scleroderma	6.18e-05	0.00116	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HSPG2—systemic scleroderma	6.18e-05	0.00116	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—MMP1—systemic scleroderma	6.18e-05	0.00116	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IRF8—systemic scleroderma	6.08e-05	0.00114	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—ITGAM—systemic scleroderma	6.08e-05	0.00114	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CD247—systemic scleroderma	6.08e-05	0.00114	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—CSK—systemic scleroderma	5.97e-05	0.00112	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—CSK—systemic scleroderma	5.97e-05	0.00112	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SMAD7—systemic scleroderma	5.93e-05	0.00112	CbGpPWpGaD
Dipyridamole—Nausea—Methotrexate—systemic scleroderma	5.93e-05	0.000301	CcSEcCtD
Dipyridamole—PDE1B—Immune System—CSK—systemic scleroderma	5.92e-05	0.00111	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—CCL2—systemic scleroderma	5.91e-05	0.00111	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—NOS3—systemic scleroderma	5.86e-05	0.0011	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—NOS3—systemic scleroderma	5.86e-05	0.0011	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IRF5—systemic scleroderma	5.82e-05	0.00109	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—MMP1—systemic scleroderma	5.81e-05	0.00109	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—EDN1—systemic scleroderma	5.73e-05	0.00108	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—EDN1—systemic scleroderma	5.73e-05	0.00108	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—TNFAIP3—systemic scleroderma	5.69e-05	0.00107	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HSPG2—systemic scleroderma	5.65e-05	0.00106	CbGpPWpGaD
Dipyridamole—PDE11A—Hemostasis—TGFB1—systemic scleroderma	5.64e-05	0.00106	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—BLK—systemic scleroderma	5.63e-05	0.00106	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—CD247—systemic scleroderma	5.61e-05	0.00105	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—CD247—systemic scleroderma	5.61e-05	0.00105	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—EDN1—systemic scleroderma	5.58e-05	0.00105	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IRF8—systemic scleroderma	5.56e-05	0.00104	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—ITGAM—systemic scleroderma	5.56e-05	0.00104	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CD247—systemic scleroderma	5.56e-05	0.00104	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—CCL2—systemic scleroderma	5.49e-05	0.00103	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—CCL2—systemic scleroderma	5.49e-05	0.00103	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CSK—systemic scleroderma	5.46e-05	0.00103	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SMAD7—systemic scleroderma	5.43e-05	0.00102	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—CTGF—systemic scleroderma	5.4e-05	0.00101	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—RHOB—systemic scleroderma	5.36e-05	0.00101	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—MMP1—systemic scleroderma	5.32e-05	0.000999	CbGpPWpGaD
Dipyridamole—ABCC4—NRF2 pathway—TGFB1—systemic scleroderma	5.22e-05	0.000981	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—TNFAIP3—systemic scleroderma	5.21e-05	0.000978	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—HSPG2—systemic scleroderma	5.18e-05	0.000973	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—BLK—systemic scleroderma	5.15e-05	0.000967	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CD247—systemic scleroderma	5.13e-05	0.000965	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—EDN1—systemic scleroderma	5.11e-05	0.000959	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—EDN1—systemic scleroderma	5.1e-05	0.000959	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—CCL2—systemic scleroderma	5.09e-05	0.000957	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HSPG2—systemic scleroderma	5.06e-05	0.00095	CbGpPWpGaD
Dipyridamole—PDE5A—Hemostasis—TGFB1—systemic scleroderma	5.03e-05	0.000945	CbGpPWpGaD
Dipyridamole—PDE10A—Hemostasis—TGFB1—systemic scleroderma	5.03e-05	0.000945	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—RHOB—systemic scleroderma	5.02e-05	0.000943	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—NOS3—systemic scleroderma	4.92e-05	0.000924	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—CCL2—systemic scleroderma	4.9e-05	0.00092	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—RHOB—systemic scleroderma	4.88e-05	0.000917	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CSK—systemic scleroderma	4.88e-05	0.000917	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—EDN1—systemic scleroderma	4.78e-05	0.000898	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—EDN1—systemic scleroderma	4.75e-05	0.000892	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—EDN1—systemic scleroderma	4.75e-05	0.000892	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HSPG2—systemic scleroderma	4.73e-05	0.000889	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—EDN1—systemic scleroderma	4.65e-05	0.000873	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—EDN1—systemic scleroderma	4.63e-05	0.000871	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CTLA4—systemic scleroderma	4.61e-05	0.000866	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—CCL2—systemic scleroderma	4.6e-05	0.000865	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HSPG2—systemic scleroderma	4.6e-05	0.000865	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—CCL2—systemic scleroderma	4.6e-05	0.000865	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—RHOB—systemic scleroderma	4.59e-05	0.000863	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CSK—systemic scleroderma	4.57e-05	0.000859	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—NOS3—systemic scleroderma	4.48e-05	0.000842	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CSK—systemic scleroderma	4.45e-05	0.000836	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—EDN1—systemic scleroderma	4.4e-05	0.000827	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—EDN1—systemic scleroderma	4.37e-05	0.000821	CbGpPWpGaD
Dipyridamole—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	4.35e-05	0.000818	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—EDN1—systemic scleroderma	4.34e-05	0.000816	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—EDN1—systemic scleroderma	4.34e-05	0.000815	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HSPG2—systemic scleroderma	4.33e-05	0.000813	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—EDN1—systemic scleroderma	4.23e-05	0.000795	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—EDN1—systemic scleroderma	4.22e-05	0.000793	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CTLA4—systemic scleroderma	4.21e-05	0.000792	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—NOS3—systemic scleroderma	4.21e-05	0.000792	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—RHOB—systemic scleroderma	4.2e-05	0.000789	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CSK—systemic scleroderma	4.18e-05	0.000786	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—NOS3—systemic scleroderma	4.1e-05	0.000771	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—NOS3—systemic scleroderma	4.1e-05	0.000771	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—MMP1—systemic scleroderma	4.03e-05	0.000757	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—EDN1—systemic scleroderma	4e-05	0.000751	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—EDN1—systemic scleroderma	3.97e-05	0.000746	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HSPG2—systemic scleroderma	3.96e-05	0.000744	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—CTGF—systemic scleroderma	3.92e-05	0.000737	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—CCL2—systemic scleroderma	3.92e-05	0.000736	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—CCL2—systemic scleroderma	3.92e-05	0.000736	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—TGFB1—systemic scleroderma	3.88e-05	0.000728	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—TGFB1—systemic scleroderma	3.88e-05	0.000728	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—NOS3—systemic scleroderma	3.85e-05	0.000724	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—NOS3—systemic scleroderma	3.83e-05	0.000719	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CSK—systemic scleroderma	3.82e-05	0.000719	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—CCL2—systemic scleroderma	3.82e-05	0.000717	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HLA-DQB1—systemic scleroderma	3.79e-05	0.000713	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—NOS3—systemic scleroderma	3.78e-05	0.00071	CbGpPWpGaD
Dipyridamole—ABCC4—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.75e-05	0.000704	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EDN1—systemic scleroderma	3.63e-05	0.000682	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL1A—systemic scleroderma	3.6e-05	0.000677	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CD40LG—systemic scleroderma	3.58e-05	0.000673	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—IL1B—systemic scleroderma	3.53e-05	0.000663	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—NOS3—systemic scleroderma	3.49e-05	0.000656	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—NOS3—systemic scleroderma	3.49e-05	0.000656	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—CCL2—systemic scleroderma	3.49e-05	0.000656	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HLA-DQB1—systemic scleroderma	3.47e-05	0.000652	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—NOS3—systemic scleroderma	3.4e-05	0.000639	CbGpPWpGaD
Dipyridamole—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.38e-05	0.000635	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL1A—systemic scleroderma	3.3e-05	0.000619	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—MMP9—systemic scleroderma	3.29e-05	0.000619	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—MMP9—systemic scleroderma	3.29e-05	0.000619	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CD40LG—systemic scleroderma	3.28e-05	0.000616	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—TGFB1—systemic scleroderma	3.25e-05	0.000611	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—CCL2—systemic scleroderma	3.24e-05	0.00061	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—CCL2—systemic scleroderma	3.24e-05	0.00061	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—CCL2—systemic scleroderma	3.17e-05	0.000595	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—NOS3—systemic scleroderma	3.11e-05	0.000584	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—CCL2—systemic scleroderma	3.01e-05	0.000565	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—CCL2—systemic scleroderma	2.97e-05	0.000558	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—CCL2—systemic scleroderma	2.97e-05	0.000557	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—TGFB1—systemic scleroderma	2.96e-05	0.000557	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—NOS3—systemic scleroderma	2.92e-05	0.000549	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—NOS3—systemic scleroderma	2.89e-05	0.000543	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—NOS3—systemic scleroderma	2.89e-05	0.000543	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—CCL2—systemic scleroderma	2.89e-05	0.000543	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—CCL2—systemic scleroderma	2.89e-05	0.000542	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—MMP9—systemic scleroderma	2.8e-05	0.000526	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—MMP9—systemic scleroderma	2.8e-05	0.000526	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—TGFB1—systemic scleroderma	2.79e-05	0.000523	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EDN1—systemic scleroderma	2.74e-05	0.000514	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—MMP9—systemic scleroderma	2.73e-05	0.000513	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—TGFB1—systemic scleroderma	2.71e-05	0.00051	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—TGFB1—systemic scleroderma	2.71e-05	0.00051	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—CCL2—systemic scleroderma	2.71e-05	0.00051	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—NOS3—systemic scleroderma	2.68e-05	0.000504	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—NOS3—systemic scleroderma	2.64e-05	0.000497	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—NOS3—systemic scleroderma	2.58e-05	0.000484	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EDN1—systemic scleroderma	2.56e-05	0.000482	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—TGFB1—systemic scleroderma	2.55e-05	0.000479	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—TGFB1—systemic scleroderma	2.53e-05	0.000476	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—TGFB1—systemic scleroderma	2.5e-05	0.000469	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—MMP9—systemic scleroderma	2.5e-05	0.000469	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EDN1—systemic scleroderma	2.49e-05	0.000468	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—CCL2—systemic scleroderma	2.48e-05	0.000466	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—NOS3—systemic scleroderma	2.35e-05	0.000442	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EDN1—systemic scleroderma	2.34e-05	0.00044	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—MMP9—systemic scleroderma	2.32e-05	0.000436	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—MMP9—systemic scleroderma	2.32e-05	0.000436	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—TGFB1—systemic scleroderma	2.31e-05	0.000434	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—TGFB1—systemic scleroderma	2.31e-05	0.000434	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—TGFB1—systemic scleroderma	2.25e-05	0.000423	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—MMP9—systemic scleroderma	2.15e-05	0.000404	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EDN1—systemic scleroderma	2.14e-05	0.000403	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—MMP9—systemic scleroderma	2.12e-05	0.000399	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—MMP9—systemic scleroderma	2.07e-05	0.000389	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—TGFB1—systemic scleroderma	2.06e-05	0.000386	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NOS3—systemic scleroderma	2.04e-05	0.000383	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NOS3—systemic scleroderma	2.04e-05	0.000383	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TGFB1—systemic scleroderma	1.93e-05	0.000363	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TGFB1—systemic scleroderma	1.91e-05	0.000359	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TGFB1—systemic scleroderma	1.91e-05	0.000359	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL1B—systemic scleroderma	1.88e-05	0.000353	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCL2—systemic scleroderma	1.87e-05	0.000352	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NOS3—systemic scleroderma	1.87e-05	0.00035	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TGFB1—systemic scleroderma	1.77e-05	0.000333	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCL2—systemic scleroderma	1.75e-05	0.000329	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TGFB1—systemic scleroderma	1.75e-05	0.000329	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL1B—systemic scleroderma	1.72e-05	0.000323	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—NOS3—systemic scleroderma	1.71e-05	0.000321	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCL2—systemic scleroderma	1.7e-05	0.00032	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TGFB1—systemic scleroderma	1.7e-05	0.00032	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.67e-05	0.000314	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NOS3—systemic scleroderma	1.67e-05	0.000313	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCL2—systemic scleroderma	1.6e-05	0.000301	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NOS3—systemic scleroderma	1.56e-05	0.000293	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NOS3—systemic scleroderma	1.52e-05	0.000285	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCL2—systemic scleroderma	1.47e-05	0.000275	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NOS3—systemic scleroderma	1.43e-05	0.000268	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.42e-05	0.000267	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFB1—systemic scleroderma	1.35e-05	0.000253	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFB1—systemic scleroderma	1.35e-05	0.000253	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—systemic scleroderma	1.34e-05	0.000251	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOS3—systemic scleroderma	1.31e-05	0.000245	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—systemic scleroderma	1.25e-05	0.000235	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TGFB1—systemic scleroderma	1.23e-05	0.000232	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—systemic scleroderma	1.22e-05	0.000229	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—systemic scleroderma	1.15e-05	0.000215	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TGFB1—systemic scleroderma	1.1e-05	0.000207	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CTGF—systemic scleroderma	1.08e-05	0.000203	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—systemic scleroderma	1.05e-05	0.000197	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TGFB1—systemic scleroderma	1.03e-05	0.000194	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TGFB1—systemic scleroderma	1e-05	0.000189	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TGFB1—systemic scleroderma	9.44e-06	0.000177	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFB1—systemic scleroderma	8.64e-06	0.000162	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NOS3—systemic scleroderma	4.69e-06	8.82e-05	CbGpPWpGaD
